Zentalis Pharmaceuticals (ZNTL)
(Delayed Data from NSDQ)
$4.22 USD
-0.14 (-3.21%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.22 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Zentalis Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 300 | 227 | 217 | 119 | 47 |
Income After Depreciation & Amortization | -300 | -227 | -217 | -119 | -47 |
Non-Operating Income | 23 | 6 | 52 | 1 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -277 | -221 | -165 | -118 | -46 |
Income Taxes | -1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | -7 | -1 | -1 |
Investment Gains/Losses | -16 | -16 | -2 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -292 | -237 | -166 | -119 | -46 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -292 | -237 | -159 | -118 | -46 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -311 | -230 | -215 | -118 | -47 |
Depreciation & Amortization (Cash Flow) | -12 | -2 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -300 | -227 | -217 | -119 | -47 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 65.41 | 52.86 | 42.69 | 28.11 | NA |
Diluted EPS Before Non-Recurring Items | -4.47 | -4.48 | -3.72 | -4.19 | NA |
Diluted Net EPS (GAAP) | -4.47 | -4.48 | -3.72 | -4.19 | NA |
Fiscal Year end for Zentalis Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 40.56 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 40.56 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 65.15 | 65.33 | 67.93 | 62.72 | 103.91 |
Income After SG&A, R&D, and Dept/Amort Expenses | -65.15 | -24.77 | -67.93 | -62.72 | -103.91 |
Non-Operating Income | -22.86 | 34.95 | 6.85 | 7.21 | 4.45 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -88.01 | 10.18 | -61.07 | -55.51 | -99.47 |
Income Taxes | 0.27 | 0.14 | -0.14 | 0.03 | -0.61 |
Minority Interest | 0.00 | -0.03 | -0.02 | -0.01 | -0.04 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | -13.70 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -88.28 | 10.04 | -60.94 | -55.54 | -112.56 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -88.28 | 10.07 | -60.92 | -55.53 | -112.53 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 71.04 | 71.19 | 73.39 | 70.61 | 60.79 |
Diluted EPS Before Non-Recurring Items | -1.24 | 0.14 | -0.83 | -0.79 | -1.85 |
Diluted Net EPS (GAAP) | -1.24 | 0.14 | -0.76 | -0.79 | -1.85 |